scholarly journals Severe skin rash in case of readministration of telaprevir in a patient who previously experienced a non severe rash

Hepatology ◽  
2012 ◽  
Vol 55 (6) ◽  
pp. 2042-2043 ◽  
Author(s):  
Nicolas Dupin ◽  
Vincent Mallet ◽  
Agnès Carlotti ◽  
Anaïs Vallet-Pichard ◽  
Stanislas Pol
Keyword(s):  
Skin Rash ◽  
Severe Rash

scholarly journals Severe Skin Rash Associated with Atazanavir

2009 ◽  
Vol 20 (1) ◽  
pp. e10-e12 ◽  
Author(s):  
Andrew Walkty ◽  
Dick Smith ◽  
Bernie Lopko ◽  
Ken Kasper
Keyword(s):  
Adverse Effect ◽  
Skin Rash ◽  
Potential Adverse Effect ◽  
Pruritic Rash ◽  
Initiation Of Therapy ◽  
Severe Rash

Three cases of severe rash associated with the use of atazanavir are described. In all cases, the rash was maculopapular and pruritic. Rash onset occurred eight to 11 days after initiation of therapy, and resolved with atazanavir discontinuation. Clinicians prescribing atazanavir should be aware of this potential adverse effect.

scholarly journals Investigating the Mechanism of Trimethoprim-Induced Skin Rash and Liver Injury

2021 ◽  
Author(s):  
Yanshan Cao ◽  
Ahsan Bairam ◽  
Alison Jee ◽  
Ming Liu ◽  
Jack Uetrecht
Keyword(s):  
Liver Injury ◽  
Skin Rash ◽  
Covalent Binding ◽  
Reactive Metabolites ◽  
Important Data ◽  
Drug Induced ◽  
Interindividual Differences ◽  
Immune Mediated ◽  
Sulfate Conjugate

Abstract Trimethoprim (TMP)-induced skin rash and liver injury are likely to involve the formation of reactive metabolites. Analogous to nevirapine-induced skin rash, one possible reactive metabolite is the sulfate conjugate of α-hydroxyTMP, a metabolite of TMP. We synthesized this sulfate and found that it reacts with proteins in vitro. We produced a TMP-antiserum and found covalent binding of TMP in the liver of TMP-treated rats. However, we found that α-hydroxyTMP is not a substrate for human sulfotransferases, and we did not detect covalent binding in the skin of TMP-treated rats. Although less reactive than the sulfate, α-hydroxyTMP was found to covalently bind to liver and skin proteins in vitro. Even though there was covalent binding to liver proteins, TMP did not cause liver injury in rats or in our impaired immune tolerance mouse model that has been able to unmask the ability of other drugs to cause immune-mediated liver injury. This is likely because there was much less covalent binding of TMP in the livers of TMP-treated mice than TMP-treated rats. It is possible that some patients have a sulfotransferase that can produce the reactive benzylic sulfate; however, α-hydroxyTMP, itself, has sufficient reactivity to covalently bind to proteins in the skin and may be responsible for TMP-induced skin rash. Interspecies and interindividual differences in TMP metabolism may be one factor that determines the risk of TMP-induced skin rash. This study provides important data required to understand the mechanism of TMP-induced skin rash and drug-induced skin rash in general.

scholarly journals A new rapid titration protocol for lamotrigine that reduces the risk of skin rash

2021 ◽  
Author(s):  
Yoonhyuk Jang ◽  
Jangsup Moon ◽  
Narae Kim ◽  
Tae‐Joon Kim ◽  
Jin‐Sun Jun ◽  
...  
Keyword(s):  
Skin Rash ◽  
Titration Protocol

scholarly journals 17. Comparative Safety of Antibiotic Therapy for Outpatient Treatment of Uncomplicated Urinary Tract Infections

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S9-S10
Author(s):  
Anne M Butler ◽  
Michael Durkin ◽  
Matthew R Keller ◽  
Yinjiao Ma ◽  
William Powderly ◽  
...  
Keyword(s):  
Renal Failure ◽  
Acute Renal Failure ◽  
Abdominal Pain ◽  
Urinary Tract ◽  
Skin Rash ◽  
Adverse Drug Events ◽  
Vulvovaginal Candidiasis ◽  
First Line ◽  
Research Support ◽  
Comparative Safety

Abstract Background Urinary tract infection (UTI) is one of the most common indications for outpatient antibiotic prescriptions in otherwise healthy women, yet the comparative safety of antibiotics for empirical therapy is not well established. We compared the risk of adverse drug events by antibiotic treatment regimen among premenopausal women with uncomplicated UTI. Methods Using the IBM MarketScan Commercial Database (2006–2015), we identified healthy, non-pregnant women aged 18–44 who were diagnosed with UTI and prescribed a same-day antibiotic with activity against common uropathogens. Patients were followed for outcomes with varying follow-up periods: 3 days (anaphylaxis), 14 days (acute renal failure, skin rash, urticaria/hives, nausea/vomiting, abdominal pain), 30 days (vaginitis/vulvovaginal candidiasis, non-C. difficile diarrhea) and 90 days (C. difficile diarrhea, pneumonia, tendinopathy, retinal detachment). We estimated propensity score-weighted hazard ratios (HR) and 95% confidence intervals (CI) using Cox proportional hazards models. Results Of 1,140,602 eligible women, the distribution of antibiotic receipt was fluoroquinolones (44%), trimethoprim-sulfamethoxazole (TMP/SMX) (28%), nitrofurantoin (24%), narrow-spectrum β-Lactam / β-Lactamase inhibitor combinations (“β-Lactams”) (3%), broad-spectrum β-Lactams (1%) and amoxicillin/ampicillin (1%). Of two first-line agents, we observed higher risk of outcomes among TMP/SMX vs. nitrofurantoin initiators: acute renal failure (HR 2.46, 95% CI 1.46–4.14), skin rash (HR 2.43, 95% CI 2.13–2.77), urticaria (HR 1.35, 95% CI 1.18–1.56), nausea/vomiting (HR 1.19, 95% CI 1.10–1.29) and abdominal pain (HR 1.14, 95% CI 1.09–1.19). Compared to nitrofurantoin, non-first-line agents (fluoroquinolones, broad-, and/or narrow-spectrum β-Lactams) were associated with higher risk of acute renal failure, skin rash, nausea/vomiting, abdominal pain, vaginitis/vulvovaginal candidiasis, diarrhea (C. difficile & non-C. difficile), pneumonia and tendinopathy. Conclusion The risk of adverse drug events differs widely by antibiotic agent, with substantial differences in first-line agents. Understanding antibiotic safety is critical to prevent suboptimal antibiotic prescribing and reduce adverse events. Disclosures Margaret A. Olsen, PhD, MPH, Merck (Grant/Research Support)Pfizer (Consultant, Grant/Research Support)

Analysis of risk factors for lenalidomide-associated skin rash in patients with multiple myeloma

2021 ◽  
pp. 1-12
Author(s):  
Tomiyuki Sugi ◽  
Yasuo Nishigami ◽  
Hirohisa Saigo ◽  
Homare Hanai ◽  
Keisuke Takabatake ◽  
...  
Keyword(s):  
Risk Factors ◽  
Multiple Myeloma ◽  
Skin Rash

Neonatal Toxic Shock Syndrome–Like Exanthematous Disease in North America

2019 ◽  
Author(s):  
Megan Culler Freeman ◽  
Stephanie Mitchell ◽  
John Ibrahim ◽  
John V Williams
Keyword(s):  
North America ◽  
Diagnostic Criteria ◽  
Skin Rash ◽  
Toxic Shock Syndrome ◽  
Disease Process ◽  
Toxic Shock ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
First Case

Abstract Neonatal toxic shock syndrome (TSS)-like exanthematous disease (NTED) is a syndrome first reported in Japan. Neonates develop systemic exanthema, thrombocytopenia, and fever usually during the first week of life. The disease is distinguished from frank TSS because affected infants are not severely ill and do not meet TSS criteria. Most infants are confirmed to be colonized with TSST-1 producing strains of S. aureus. Suggested diagnostic criteria for NTED include a skin rash with generalized macular erythema and one of the following symptoms: fever >38.0°C, thrombocytopenia <150 x103uL, or low positive C-reactive protein (1-5 mg/dL) in the absence of another known disease process. NTED is common in Japanese NICUs, but outside Japan, only one case has been reported in France. We describe the first case of NTED reported in North America.

A NTICONVULSANT HYPERSENSITIVITY SYNDROME MIMICKING A VIRAL ILLNESS WITH SKIN RASH: A CASE REPORT

2013 ◽  
Vol 68 (3) ◽  
pp. 232-233 ◽  
Author(s):  
V Gérard ◽  
E Delgrange ◽  
C de Halleux ◽  
D Vanpee
Keyword(s):  
Case Report ◽  
Skin Rash ◽  
Hypersensitivity Syndrome ◽  
Viral Illness
Sign in / Sign up

Export Citation Format

Share Document